647
Views
14
CrossRef citations to date
0
Altmetric
Cardiovascular

Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials

, , &
Pages 1441-1451 | Received 17 Jan 2016, Accepted 04 Apr 2016, Published online: 25 May 2016

References

  • Ho PM, Tsai TT, Maddox TM, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 2010;3:261-6
  • Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol 2014;742:47-54
  • Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010;103:363-75
  • Legrand D, Legrand V. Adherence to antiplatelet therapy in patients with coronary artery disease. Rev Med Liege 2010;65:304-10
  • Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011;104:561-9
  • Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-82
  • Tantry US, Jeong YH, Navarese EP, et al. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2013;11:447-62
  • Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66
  • Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011;22:579-87
  • Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012;10:529-42
  • Kubica A, Koziński M, Grześk G, Goch A. Clinical significance of interactions between clopidogrel and proton pump inhibitors. Kardiol Pol 2011;69:610-16
  • Karaźniewicz-Łada M, Danielak D, Główka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother 2012;13:663-83
  • Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
  • Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009;3:e123-30
  • Canpolat U, Yorgun H, Atalar E. Simultaneous subacute thrombosis of bare metal coronary stents in two different arteries early after clopidogrel cessation. Cardiol J 2012;19:309-13
  • Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2
  • Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30
  • Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
  • Zghal FM, Amri A, Mourali MS, et al. Bare metal stent thrombosis in patients with acute coronary syndrome. Circ J 2012;76:634-40
  • Qureshi Z, Hobson AR. Clopidogrel “resistance”: where are we now? Cardiovasc Ther 2013;31:3-11
  • Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance – clinically and chemically relevant? Curr Med Chem 2010;17:4578-86
  • Steinwender C, Hartenthaler B, Lambert T, et al. Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. EuroIntervention 2009;4:593-9
  • Kubica A, Kasprzak M, Obonska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology 2015;95:50-8
  • Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 2014;174:186-93
  • Zhu B, Zhao Z, McCollam P, et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011;27:633-41
  • Pallares MJ, Powers ER, Zwerner PL, et al. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother 2009;43:259-67
  • Latry P, Martin-Latry K, Lafitte M, et al. Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. EuroIntervention 2012;7:1413-19
  • Nordstrom BL, Simeone JC, Zhao Z, et al. Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. Am J Cardiovasc Drugs 2013;13:263-71
  • Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012;60:1333-9
  • Ferreira-González I, Marsal JR, Ribera A, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010;122:1017-25
  • Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012;15;109:214-18
  • Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009;104:175-81
  • Mayer F, Bargagli AM, Belleudi V, et al. Socioeconomic position and appropriate antiplatelet therapy after percutaneous coronary intervention: a population-based cohort study in Rome (Lazio Region, Central Italy). Epidemiol Prev 2014;38:123-31
  • Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 2010;122:1085-90
  • Shimony A, Zahger D, Ilia R, et al. Impact of the community’s socioeconomic status on characteristics and outcomes of patients undergoing percutaneous coronary intervention. Int J Cardiol 2010;144:379-82
  • Whitley HP. Monetary value of a prescription assistance program service in a rural family medicine clinic. J Rural Health 2011;27:190-5
  • Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care 2010;16:290-7
  • Burke JP, Sander S, Shah H, et al. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin 2010;26:1023-30
  • Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 2010;29:1995-2001
  • Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J 2014;167:51-8
  • Choudhry NK, Avorn J, Glynn RJ, et al. Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97
  • Kulik A, Desai NR, Shrank WH, et al. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. Circulation 2013;128(11 Suppl 1):S219-S25
  • Sengstock D, Vaitkevicius P, Salama A, Mentzer RM. Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence. Drugs Aging 2012;29:93-103
  • Roth GA, Morden NE, Zhou W, et al. Clopidogrel use and early outcomes among older patients receiving a drug eluting coronary artery stent. Circ Cardiovasc Qual Outcomes 2012;5:103-12
  • Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9
  • Muntner P, Mann DM, Woodward M, et al. Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol 2011;108:822-7
  • Dehghani P, Chopra V, Bell A, et al. Southern Saskatchewan ticagrelor registry experience. Patient Prefer Adherence 2014;8:1427-35
  • Garavalia L, Garavalia B, Spertus JA, Decker C. Exploring patients’ reasons for discontinuance of heart medications. J Cardiovasc Nurs 2009;24:371-9
  • Cutlip DE, Kereiakes DJ, Mauri L, et al. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 2015;8:404-10
  • Rossini R, Baroni M, Musumeci G, Gavazzi A. Oral antiplatelet therapy after drug-eluting stent implantation: adherence and side-effects. J Cardiovasc Med (Hagerstown) 2013;14:81-90
  • Armero S, Bonello L, Berbis J, et al. Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. Am J Cardiol 2011;108:1710-13
  • Kovacic JC, Lee P, Karajgikar R, et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary “real-world” practice. J Interv Cardiol 2012;25:482-92
  • Simeone JC, Molife C, Marrett E, et al. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs 2015;15:337-50
  • Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol 2014;173:120-1
  • Belchikov YG, Koenig SJ, Dipasquale EM. Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy 2013;33:882-7
  • Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care 2015;4:555-60
  • Spinler SA. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Pharmacotherapy 2009;29:812-21
  • Alexopoulos D, Stavrou K, Koniari I, et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 2014;112:551-7
  • Larmore C, Effron MB, Molife C, et al. “Real-world” comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 2015: published online 18 November 2015, doi: 10.1002/ccd.26279
  • Vrijens B, Claeys MJ, Legrand V, et al. Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Br J Clin Pharmacol 2014;77:746-55
  • Thim T, Johansen MB, Chisholm GE, et al. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014;14:100
  • Decker C, Garavalia L, Garavalia B, Spertus JA. Clopidogrel-taking behavior by drug-eluting stent patients: discontinuers versus continuers. Patient Prefer Adherence 2008;2:167-75
  • Cruden NL, Din JN, Janssen C, et al. Delay in filling first clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial infarction. J Am Heart Assoc 2014;3:e000669
  • Bally K, Buechel RR, Buser P, et al. Discontinuation of secondary prevention medication after myocardial infarction – the role of general practitioners and patients. Swiss Med Wkly 2013;143:w13896
  • Syed IA, Riaz A, Ryan A, Reilly MO. Secondary prevention for coronary artery disease: are we following the guidelines? Ir J Med Sci 2010;179:535-7
  • Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction – a hospital registry–primary care linked cohort (MINAP–GPRD). Eur Heart J 2011;32:2376-86
  • Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J 2007;15:148-50
  • Davlouros P, Gizas V, Stavrou K, et al. DES thrombosis related to antiplatelet therapy noncompliance: a consequence of the Greek financial crisis. Int J Cardiol 2013;168:4497-9
  • Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One 2013;8:e61735
  • Kronish IM, Rieckmann N, Shimbo D, et al. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol 2010;106:1090-94
  • Walter PN, Tsakiris DA, Romanens M, et al. Antiplatelet resistance in outpatients with monitored adherence. Platelets 2014;25:532-8
  • Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J 2009;158:925-32
  • Siller-Matula J, Lang IM, Neunteufl T, et al. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One 2014;22:e102701
  • Alexopoulos D, Xanthopoulou I, Stavrou K, et al. Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy. Can J Cardiol 2013;29:1743.e13-4
  • Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol 2015: published online 23 June 2015, doi: 10.5603/KP.a2015.0117
  • Moussa ID, Colombo A. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations. Catheter Cardiovasc Interv 2009;74:1047-54
  • Garavalia L, Ho PM, Garavalia B, et al. Clinician–patient discord: exploring differences in perspectives for discontinuing clopidogrel. Eur J Cardiovasc Nurs 2011;10:50-5
  • Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. Am J Cardiol 2014;114:1479-84
  • Hamrosi K, Dickinson R, Knapp P, et al. It’s for your benefit: exploring patients’ opinions about the inclusion of textual and numerical benefit information in medicine leaflets. Int J Pharm Pract 2013;21:216-25
  • Bottorff MB, Nutescu EA, Spinler S. Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy 2007;27:1145-62
  • Kubica A. Health Education and the Efficacy of Antiplatelet Therapy in Myocardial Infarction Survivors on the Background of Selected Factors. Toruń, Poland: Wydawnictwo Naukowe Uniwersytetu Mikołaja Kopernika, 2012
  • Kubica A, Pufal J, Moczulska B, et al. Effectiveness of health education in patients hospitalized in the department of cardiology. Psychiatria w Praktyce Ogólnolekarskiej 2005;2:61-8
  • Calvert AB, Kramer JM, Anstrom KJ, et al. Patient-focused intervention to improve long term adherence to evidence-based medications: a randomized trial. Am Heart J 2012;163:657-65
  • Hedegaard U, Kjeldsen LJ, Pottegard A, et al. Multifaceted intervention including motivational interviewing to support medication adherence after stroke/transient ischemic attack: a randomized trial. Cerebrovasc Dis Extra 2014;4:221-34
  • Palacio AM, Uribe C, Hazel-Fernandez L. Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial. J Gen Intern Med 2015;30:469-75
  • Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-27
  • Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns 2014;94:261-8
  • Schwalm JD, Ivers NM, Natarajan MK, et al. Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI). Am Heart J 2015;170:903-13
  • McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79
  • Jung JA, Kim TE, Kim JR, et al. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study. Clin Ther 2013;35:985-94

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.